Vascular Endothelial Growth Factor (VEGF) is a potent angiogenic cytokine that stimulates endothelial cell proliferation, migration, and tube formation to build new blood vessels. It increases vascular permeability through disruption of endothelial Tight junctions, playing critical roles in wound healing, inflammation, embryonic development, and pathological Neovascularization in Cancer and chronic inflammatory diseases. VEGF-A is the primary isoform responsible for physiological and pathological angiogenesis.
Think of VEGF as a construction manager who shows up whenever a neighborhood needs new roads and plumbing. When tissue is injured or starved of oxygen, cells send out an emergency call, and VEGF arrives with blueprints for new blood vessels. The construction crew (endothelial cells) follows VEGF's instructions to proliferate, migrate through the tissue, and form hollow tubes that become functional blood vessels. But VEGF doesn't just build—it also makes the existing pipes leaky by loosening the joints between bricks (endothelial cells), allowing fluid and immune cells to flood into the area. This leakiness is helpful during wound healing (bringing resources to the construction site), but catastrophic when tumors hijack VEGF to build their own blood supply—creating chaotic, leaky vessels that support cancer growth and spread. In chronic inflammation, VEGF keeps building unnecessary roads, worsening swelling and tissue damage. The key is knowing when to call the construction manager and when to send them home.
VEGF production is primarily triggered by hypoxia (low oxygen), which stabilizes HIF-1α (Hypoxia-Inducible Factor 1-alpha). Under normoxic conditions, prolyl hydroxylases (PHDs) mark HIF-1α for degradation via the ubiquitin-proteasome pathway. When O₂ drops below ~5%, PHD activity falls, HIF-1α accumulates, translocates to the nucleus, and binds hypoxia response elements (HREs) on the VEGF gene promoter, dramatically upregulating VEGF-A transcription.
VEGF signaling cascade:
VEGF-A → VEGFR-2 (KDR/Flk-1) binding on endothelial cells → receptor dimerization and autophosphorylation → activation of multiple pathways:
- PLCγ → PKC → MAPK/ERK pathway → endothelial cell proliferation
- PI3K → AKT pathway → eNOS activation → nitric oxide production → vasodilation and vascular permeability
- FAK → paxillin → cytoskeletal reorganization → endothelial migration
- Src → VE-cadherin phosphorylation → disruption of adherens junctions → increased permeability
VEGFR-1 (Flt-1) also binds VEGF but primarily acts as a decoy receptor, sequestering VEGF to fine-tune availability for VEGFR-2 signaling.
graph TD
A["Hypoxia < 5% O₂"] --> B["HIF-1α stabilization"]
B --> C[VEGF-A gene transcription]
C --> D[VEGF-A secretion]
D --> E[VEGFR-2 binding]
E --> F[Receptor dimerization]
F --> G1["PLCγ/PKC/ERK"]
F --> G2[PI3K/AKT/eNOS]
F --> G3[FAK/paxillin]
F --> G4[Src/VE-cadherin]
G1 --> H1[Proliferation]
G2 --> H2[Vasodilation & Permeability]
G3 --> H3[Migration]
G4 --> H4[Junction disruption]
H1 --> I[Angiogenesis]
H2 --> I
H3 --> I
H4 --> I
J[VEGFR-1 Flt-1] --> K[Decoy receptor]
K --> L[Sequesters VEGF-A]
L --> M[Fine-tunes VEGFR-2 signaling]
Cellular sources of VEGF:
Vascular permeability mechanism:
VEGF induces phosphorylation of Tight junctions proteins (claudins, occludin, ZO-1) and adherens junction proteins (VE-cadherin), causing their internalization and degradation. This creates gaps between endothelial cells, allowing plasma proteins and immune cells to extravasate—the molecular basis of edema in inflammation.
VEGF sits at the intersection of healing and pathology, making it central to cPNI practice across multiple conditions:
Wound healing and chronic wounds:
During the proliferative phase (days 3-21 post-injury), M2 macrophages secrete VEGF to drive Neovascularization. Inadequate VEGF production (common in diabetes, chronic inflammation, malnutrition, or chronic stress with elevated Cortisol) results in non-healing wounds. Conversely, excessive VEGF without proper resolution mechanisms leads to pathological angiogenesis and fibrotic scarring. The clinical goal is to ensure adequate VEGF during the proliferative window, followed by timely downregulation via Specialized pro-resolving mediators (SPMs) like Resolvins (RvD1, RvE1) and Protectins (PD1).
Cancer:
Tumors hijack VEGF signaling for survival—constitutive HIF-1α activation (even under normoxia due to metabolic reprogramming) drives continuous VEGF production. Tumor vasculature is chaotic, leaky, and poorly organized, contributing to Hypoxia (creating a vicious cycle), immune evasion, and metastatic potential. Anti-VEGF therapies (bevacizumab, sunitinib) target this pathway but can cause adverse effects (hypertension, impaired wound healing, proteinuria). From an evolutionary medicine perspective, this represents antagonistic pleiotropy—the same mechanism essential for wound survival becomes lethal when coopted by malignant cells.
Chronic inflammation:
In conditions like rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis, persistent VEGF expression drives pathological angiogenesis and sustains inflammatory cell infiltration. VEGF increases vascular permeability, worsening tissue edema and damage. Metaflammation in obesity involves adipocyte-derived VEGF contributing to dysfunctional adipose tissue expansion and insulin resistance.
Diabetic complications:
Retinal hypoxia in diabetes triggers excessive VEGF production → diabetic retinopathy with leaky, fragile vessels → vision loss. Similarly, diabetic nephropathy involves VEGF dysregulation in glomerular endothelium. This reflects the Selfish Brain principle—systemic metabolic dysfunction compromising peripheral tissue oxygenation.
Clinical thresholds and biomarkers:
- Serum VEGF >500 pg/mL often correlates with active malignancy or severe inflammation
- Wound fluid VEGF peaks 3-7 days post-injury in normal healing
- Low baseline VEGF (<200 pg/mL) with poor wound healing suggests impaired angiogenic capacity
- VEGF:sFlt-1 ratio <38 in pregnancy indicates preeclampsia risk
Intervention implications:
- Enhance physiological VEGF: Intermittent hypoxic training, moderate exercise (lactate → HIF-1α), Omega-3 fatty acids (EPA/DHA balance VEGF via SPMs), adequate protein for collagen synthesis
- Suppress pathological VEGF: Anti-inflammatory nutrition (polyphenols like Quercetin, Curcumin), Specialized pro-resolving mediators (SPMs) supplementation, metabolic flexibility to reduce chronic HIF-1α activation
- Optimize timing: VEGF is essential days 3-14 of healing, but should decline by week 3—interventions must respect this temporal window
- VEGF-A is the most important isoform for angiogenesis; other isoforms (VEGF-B, C, D, PlGF) have distinct roles
- Hypoxia threshold: Oxygen tension <5% (normal tissue ~5-10%) triggers HIF-1α stabilization and VEGF transcription
- Dual receptors: VEGFR-2 (KDR) mediates angiogenesis; VEGFR-1 (Flt-1) acts as decoy and regulator
- Permeability increase: VEGF increases vascular permeability 50,000× more than histamine on a molar basis
- Half-life: Secreted VEGF has a plasma half-life of ~30 minutes, requiring continuous production for sustained effects
- Peak expression in wounds: VEGF levels peak 3-7 days post-injury, plateau through day 10-14, then decline during remodeling
- Tumor correlation: 90% of solid tumors overexpress VEGF; serum levels >1000 pg/mL associated with poor prognosis
- Anti-VEGF therapy risks: Bevacizumab increases cardiovascular events 2-3×, impairs wound healing, causes proteinuria >1g/day in 20% of patients
- Exercise effect: Moderate aerobic exercise increases VEGF 2-4× transiently, promoting healthy angiogenesis without pathology
- Resolution regulation: Resolvins (RvD1, RvE1) downregulate VEGF by 40-60% in experimental models, promoting vascular normalization
- HIF-1α — master transcription factor that directly activates VEGF gene expression under hypoxic conditions (<5% O₂)
- Angiogenesis — VEGF is the primary endothelial mitogen driving new blood vessel formation in development and repair
- Wound healing — essential during proliferative phase (days 3-21) for vascular regeneration; M2 macrophages are major source
- Macrophages — M2 polarization produces VEGF for tissue repair; M1 macrophages produce less VEGF but more TNF-α
- Hypoxia — low oxygen is the primary physiological trigger for VEGF via HIF-1α stabilization
- Inflammation — VEGF increases vascular permeability causing edema; sustained production in chronic inflammation drives pathology
- Cancer — tumors constitutively produce VEGF for pathological angiogenesis independent of oxygen status
- Specialized pro-resolving mediators (SPMs) — Resolvins, Protectins, and Maresins downregulate VEGF to promote resolution and vascular normalization
- Tight junctions — VEGF disrupts claudins, occludin, and ZO-1 to increase endothelial permeability
- Fibroblasts — produce VEGF under hypoxic stress and in response to TGF-beta during wound healing and Fibrosis
- diabetes — retinopathy and nephropathy involve pathological VEGF overproduction from chronic tissue hypoxia
- MAS receptor — Ang 1-7 signaling via MAS suppresses VEGF, CTGF, and JNK pathways to reduce fibrosis and tumor angiogenesis
- Insulin resistance — adipocyte-derived VEGF contributes to dysfunctional adipose tissue expansion in obesity
- Endothelial dysfunction — excessive VEGF causes endothelial activation, while deficiency impairs repair capacity
- Matrix metalloproteinases (MMPs) — MMP-2 and MMP-9 work with VEGF to degrade Extracellular Vesicles allowing endothelial migration
- Nitric Oxide — VEGF activates eNOS via AKT pathway producing NO for vasodilation and permeability
- Exercise — moderate intensity transiently increases VEGF promoting healthy muscle vascularization
- Omega-3 fatty acids — EPA and DHA regulate VEGF through SPM production preventing pathological angiogenesis
- Lactate — elevated lactate (from Anaerobic Glycolysis or Warburg Effect) stabilizes HIF-1α independent of oxygen, driving VEGF
- Atherosclerosis — plaque hypoxia triggers VEGF-driven intraplaque angiogenesis with fragile leaky vessels
- Cortisol — chronic elevation impairs VEGF production via glucocorticoid receptor suppression of HIF-1α transcriptional activity
- Preeclampsia — imbalance between VEGF and soluble VEGFR-1 (sFlt-1) causes endothelial dysfunction
- Intermittent Living — intermittent hypoxic exposure optimally upregulates VEGF and angiogenic capacity without pathology
- Module 4: VEGF in immune-metabolic integration and wound healing physiology
- Module 5: VEGF regulation by specialized pro-resolving mediators and resolution pharmacology